Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-07-25

Clinical Trial Update: A Safety Study of Mirikizumab (LY3074828) [Phase 1]

View source ↗

Summary

Phase 1 safety study of mirikizumab (LY3074828) in psoriasis completed; results posted in 2024. The study assessed safety and tolerability in adults with psoria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Psoriasis | Phase 1 | Status: COMPLETED | Results posted: 2024-07-25